Gary E Landreth

List of Publications by Citations

Source: https://exaly.com/author-pdf/6610642/gary-e-landreth-publications-by-citations.pdf

Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 89
 16,301
 49
 97

 papers
 citations
 h-index
 g-index

 97
 18,673
 8.5
 6.38

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
89	Inflammation and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000 , 21, 383-421	5.6	3490
88	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405	24.1	2760
87	ApoE-directed therapeutics rapidly clear Eamyloid and reverse deficits in AD mouse models. <i>Science</i> , 2012 , 335, 1503-6	33.3	776
86	ApoE promotes the proteolytic degradation of Abeta. <i>Neuron</i> , 2008 , 58, 681-93	13.9	680
85	Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. <i>Brain</i> , 2005 , 128, 1442-53	11.2	455
84	Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer& disease. <i>Journal of Neuroscience</i> , 2003 , 23, 7504-9	6.6	424
83	TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer S disease mouse models. <i>Journal of Experimental Medicine</i> , 2015 , 212, 287-95	16.6	407
82	The role of microglia in amyloid clearance from the AD brain. <i>Journal of Neural Transmission</i> , 2010 , 117, 949-60	4.3	393
81	Inflammation, microglia, and Alzheimer's disease. <i>Neurobiology of Disease</i> , 2010 , 37, 503-9	7.5	350
80	Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 443-8	11.5	332
79	Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. Journal of Neuroscience, 2004 , 24, 9838-46	6.6	331
78	Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. <i>Journal of Biological Chemistry</i> , 2001 , 276, 18169-77	5.4	293
77	Mechanisms underlying the rapid peroxisome proliferator-activated receptor-Emediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. <i>Journal of Neuroscience</i> , 2012 , 32, 10117-28	6.6	278
76	Microglia and inflammation in Alzheimer's disease. CNS and Neurological Disorders - Drug Targets, 2010 , 9, 156-67	2.6	275
75	Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 10601-6	11.5	262
74	Rosiglitazone monotherapy in mild-to-moderate Alzheimers disease: results from a randomized, double-blind, placebo-controlled phase III study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 30, 131-46	2.6	237
73	PPARs in the brain. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007 , 1771, 1031	I-4 5 5	230

(2018-2008)

72	PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. <i>Neurotherapeutics</i> , 2008 , 5, 481-9	6.4	229
71	Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimers Disease. <i>Journal of Neuroscience</i> , 2017 , 37, 637-647	6.6	225
70	Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. <i>Journal of Neuroscience</i> , 2008 , 28, 6983-95	6.6	205
69	TREM2 in Neurodegenerative Diseases. <i>Molecular Neurodegeneration</i> , 2017 , 12, 56	19	176
68	The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. <i>Journal of Neuroscience</i> , 2005 , 25, 7805-12	6.6	175
67	Specific functions for ERK/MAPK signaling during PNS development. <i>Neuron</i> , 2011 , 69, 91-105	13.9	153
66	MAPSing CNS development and cognition: an ERKsome process. <i>Neuron</i> , 2009 , 61, 160-7	13.9	145
65	A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. <i>Archives of Neurology</i> , 2011 , 68, 45-50		145
64	Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 17115-20	11.5	134
63	Evidence for impaired amyloid ©clearance in Alzheimer disease. Alzheimer Research and Therapy, 2013 , 5, 33	9	133
62	A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1. <i>Learning and Memory</i> , 2003 , 10, 26-39	2.8	128
61	The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. <i>Journal of Neuroscience</i> , 2011 , 31, 843-50	6.6	127
60	The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in AlzheimerS disease: therapeutic implications. <i>CNS Drugs</i> , 2008 , 22, 1-14	6.7	121
59	Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. <i>Journal of Biological Chemistry</i> , 2006 , 281, 20842-20850	5.4	106
58	Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer\$ disease. <i>Journal of Neuroscience</i> , 2015 , 35, 6532-43	6.6	104
57	The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. <i>Journal of Neuroscience</i> , 2015 , 35, 3190-200	6.6	98
56	Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer Eamyloidosis mouse model. <i>Journal of Neuroscience</i> , 2011 , 31, 15962-71	6.6	96
55	The Trem2 R47H variant confers loss-of-function-like phenotypes in AlzheimerS disease. <i>Molecular Neurodegeneration</i> , 2018 , 13, 29	19	95

54	Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. <i>Current Alzheimer Research</i> , 2007 , 4, 159-64	3	87
53	Targeting innate immunity for neurodegenerative disorders of the central nervous system. <i>Journal of Neurochemistry</i> , 2016 , 138, 653-93	6	87
52	Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer's disease: the emerging role for microglia?. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 77, 148-164	9	8o
51	In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. <i>Molecular Neurodegeneration</i> , 2013 , 8, 13	19	79
50	Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. <i>Journal of Neuroscience</i> , 2014 , 34, 12538-46	6.6	72
49	Nuclear receptors in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2014 , 72 Pt A, 104-16	7.5	67
48	ERK1-deficient mice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 2005 , 175, 2374-80	5.3	66
47	Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facial-cutaneous and related syndromes. <i>Journal of Neuroscience</i> , 2012 , 32, 8663-77	6.6	65
46	Response to comments on "ApoE-directed therapeutics rapidly clear Emyloid and reverse deficits in AD mouse models". <i>Science</i> , 2013 , 340, 924-g	33.3	59
45	Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor Agonist Treatment Reduces Amyloid Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. <i>Journal of Biological Chemistry</i> , 2015 , 290, 21591-602	5.4	58
44	Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. Microscopy Research and Technique, 2001 , 54, 59-70	2.8	58
43	Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , 2012 , 32, 15112	2-23 2-23	55
42	Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer S disease. <i>Neuropharmacology</i> , 2017 , 123, 465-476	5.5	53
41	PPARgamma agonists as new therapeutic agents for the treatment of Alzheimers disease. <i>Experimental Neurology</i> , 2006 , 199, 245-8	5.7	49
40	Activation of the nuclear receptor PPARIIs neuroprotective in a transgenic mouse model of AlzheimerS disease through inhibition of inflammation. <i>Journal of Neuroinflammation</i> , 2015 , 12, 7	10.1	48
39	Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. <i>Annals of Neurology</i> , 2001 , 49, 276	9.4	48
38	Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. <i>Neurobiology of Aging</i> , 2014 , 35, 2091-5	5.6	45
37	Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. <i>Journal of Lipid Research</i> , 2017 , 58, 1937-1949	6.3	43

(2016-2018)

36	Pharmacological Inhibition of ERK Signaling Rescues Pathophysiology and Behavioral Phenotype Associated with 16p11.2 Chromosomal Deletion in Mice. <i>Journal of Neuroscience</i> , 2018 , 38, 6640-6652	6.6	39
35	Active PSF shaping and adaptive optics enable volumetric localization microscopy through brain sections. <i>Nature Methods</i> , 2018 , 15, 583-586	21.6	39
34	Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2015 , 35, 9173-81	6.6	38
33	A randomized controlled study to evaluate the effect of bexarotene on amyloid-land apolipoprotein E metabolism in healthy subjects. <i>Alzheimera</i> , and Dementia: Translational Research and Clinical Interventions, 2016 , 2, 110-120	6	37
32	ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. <i>Journal of NeuroImmune Pharmacology</i> , 2016 , 11, 61-72	6.9	36
31	Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. <i>Journal of Neuroinflammation</i> , 2004 , 1, 11	10.1	36
30	ERK/MAPK signaling and autism spectrum disorders. <i>Progress in Brain Research</i> , 2018 , 241, 63-112	2.9	35
29	Three-dimensional nanoscopy of whole cells and tissues with in situ point spread function retrieval. <i>Nature Methods</i> , 2020 , 17, 531-540	21.6	32
28	Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. <i>Neurobiology of Disease</i> , 2020 , 142, 104956	7.5	28
27	TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment. <i>Glia</i> , 2019 , 67, 1873-1892	9	28
26	ERK2 Alone Drives Inflammatory Pain But Cooperates with ERK1 in Sensory Neuron Survival. Journal of Neuroscience, 2015 , 35, 9491-507	6.6	27
25	Plaque-associated myeloid cells derive from resident microglia in an Alzheimer's disease model. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	22
24	Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy. <i>Scientific Reports</i> , 2016 , 6, 33176	4.9	21
23	PPARÆagonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1E9 astrocytes. <i>Glia</i> , 2019 , 67, 146-159	9	21
22	Dentate Gyrus Development Requires ERK Activity to Maintain Progenitor Population and MAPK Pathway Feedback Regulation. <i>Journal of Neuroscience</i> , 2015 , 35, 6836-48	6.6	20
21	Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation. <i>Annual Review of Pharmacology and Toxicology</i> , 2019 , 59, 237-261	17.9	20
20	Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions. <i>Molecular and Cellular Biology</i> , 2015 , 35, 1238-53	4.8	19
19	Retinoids and motor neuron disease: Potential role in amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2016 , 360, 115-20	3.2	17

18	AlExtraction from Murine Brain Homogenates. <i>Bio-protocol</i> , 2016 , 6,	0.9	16
17	INPP5D expression is associated with risk for Alzheimer\$ disease and induced by plaque-associated microglia. <i>Neurobiology of Disease</i> , 2021 , 153, 105303	7.5	16
16	Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018 , 15, 43	10.1	12
15	Microglia in central nervous system diseases. <i>Journal of NeuroImmune Pharmacology</i> , 2009 , 4, 369-70	6.9	11
14	Physiological stress and nerve growth factor treatment regulate stress-activated protein kinase activity in PC12 cells. <i>Journal of Neurobiology</i> , 1998 , 36, 537-49		7
13	Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. <i>Molecular Neurodegeneration</i> , 2020 , 15, 62	19	7
12	Chronic impairment of ERK signaling in glutamatergic neurons of the forebrain does not affect spatial memory retention and LTP in the same manner as acute blockade of the ERK pathway. <i>Hippocampus</i> , 2017 , 27, 1239-1249	3.5	6
11	The effect of amyloid on microglia-neuron interactions before plaque onset occurs independently of TREM2 in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020 , 145, 105072	7.5	5
10	The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease <i>Science Translational Medicine</i> , 2022 , 14, eabl7634	17.5	3
9	PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in AlzheimerS disease <i>Genome Medicine</i> , 2022 , 14, 17	14.4	2
8	Therapeutic potential of niacin in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040679	1.2	1
7	Impact of PLCG2 expression on Microglial Biology and Disease Pathogenesis in Alzheimer\$ Disease <i>Alzheimer and Dementia</i> , 2021 , 17 Suppl 2, e058740	1.2	O
6	Lipidated APOE has effects on cognitive function that are independent of amyloid-[pathology. <i>Brain</i> , 2015 , 138, 3470-2	11.2	
5	Neural-specific deletion of ERK2 results in frontal cortical neuropil thread formation and astrogliosis. <i>FASEB Journal</i> , 2007 , 21, A24	0.9	
4	02-07-06: The R47H Trem2 Variant Modifies Alzheimer\$ Disease Pathology and Neuroinflammation in a Novel Knock-In Mouse Model 2016 , 12, P243-P243		
3	P3-012: Advancing Therapeutics for Neuroinflammation in Alzheimer Disease: Clinical Development Considerations 2016 , 12, P822-P822		
2	The role of microglia niacin receptor (HCAR2) in Alzheimer's disease <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e052716	1.2	
1	PLCG2 expression is associated with plaque-associated microglia in Alzheimer\$ disease <i>Alzheimer</i> \$ and Dementia, 2021 , 17 Suppl 3, e054755	1.2	